Fig. 4

Sequential treatment of anti-PD-1 therapy followed by elraglusib significantly reduces growth of intracranial B16 melanoma. A Schematic representation of treatment regime. B Survival curves of mice with and without treatment as indicated (n = 10; total number of mice: 50). P values shown in Additional file 2: Table 2. C B16 metastasis at day 8 (treatments on the left) or day 14 (sequential treatment on the right) with total flux (photons/second) values depicted in the histogram. Luminescent image (bottom) shows 1 example of each group (n = 5 mice per condition). D H&E staining of brains taken at day 8 (after treatment with DMSO, elraglusib, anti-PD-1 mAb or combined treatment) or day 14 (sequential treatment) E Transcription of PD-1, LAG-3, TIGIT and CXCR3 in splenic CD8 + T cells from mice treated as shown. Spleens were taken at day 8 (after treatment with DMSO, elraglusib, anti-PD-1 mAb or combined treatment) or day 14 (sequential treatment). (B–C) Represent two pooled experiments (E) Data shown from one individual experiment, representative of two independent experiments. Groups are compared using unpaired t test. *p < 0.05, **p < 0.01, ***p < 0.001. Data are represented as mean ± SEM